Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Wayne State University
Sponsor:
Information provided by (Responsible Party):
Mark Greenwald, PhD, Wayne State University
ClinicalTrials.gov Identifier:
NCT01392092
First received: July 11, 2011
Last updated: March 20, 2014
Last verified: March 2014
  Purpose

N-acetylcysteine (NAC) is a medication that the Food and Drug Administration (FDA) has approved for several medical uses, such as dissolving mucus in patients with breathing problems, treating overdose from acetaminophen (Tylenol), and protecting the kidneys from toxic substances.

Some recent studies suggest that NAC could be useful in the treatment of other disorders including addictions. One purpose of this study is to determine whether NAC alters the level of brain glutamate (a chemical that excites brain cells). The other main purpose is to determine whether NAC affects how much cocaine people use.


Condition
Cocaine Abuse or Dependence
Cocaine Related Disorders

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers

Resource links provided by NLM:


Further study details as provided by Wayne State University:

Estimated Enrollment: 15
Study Start Date: July 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Inpatient Phase: Participants will live on an inpatient research unit at least 2 consecutive nights and possibly up to 20 consecutive nights. Participants cannot have visitors and will not be allowed to leave the inpatient unit (except with a staff escort) unless they drop out of the study. We will collect daily urine samples to make sure participants are not using any drugs except those in the study. In addition, each morning, afternoon and evening participants will receive a capsule containing placebo (a blank) or different doses of N-acetylcysteine.

Participants will take part in multiple trials (up to 9 sessions) where they will be given a standard amount of powder (identified as Drug A or Drug B) to inhale through a straw into their nose. The powder will contain placebo (a powder containing no drug) or different doses of cocaine. We will measure how participants are feeling using questionnaires and we will record vital signs—including breathing rate, blood oxygen level, heart rate, and blood pressure.

Participants will also be asked to perform a 3-hour computer task that allows them to work for Drug A, Drug B, or money. At the end of the computer task participants will receive the amount of drug they earned and a receipt for the amount of money they earned.

On each Monday of the inpatient stay, participants will be escorted to Harper Hospital for a special type of magnetic resonance imaging (MRI) scan, known as magnetic resonance spectroscopy (MRS). This is a non-invasive way to study brain chemistry. Participants will take part in a total of two (2) MRI scans. The total length of each brain scan will be about 2 hours.

Additionally on each Monday of the inpatient stay we will test the sensitivity of the participants brain to magnetic stimulation. A small magnet will be placed on top of the head so that a small electrical current is generated inside the brain. This procedure is called transcranial magnetic stimulation (TMS). We will stimulate the part of the brain that controls finger movement. Three recording electrodes (metal sensors like those used for EKG) will be placed on the right thumb and index fingers. We will measure the effects of different amounts of magnetic stimulation on the muscle activity of the thumb and index fingers (as seen on a computer screen). We will also ask participants to push a lever with their finger during parts of the procedure. These tasks will last about 2 hours.

To complete the study, a minimum stay of 16 inpatient nights is required. The maximum stay is 20 inpatient nights.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cocaine abusing or dependent research volunteers

Criteria

Inclusion Criteria:

  • Male and female volunteers (18-55 years of age)
  • Must meet DSM-IV criteria for current Cocaine Abuse or Dependence and wish to participate in research.
  • Positive urine test for cocaine.
  • Candidates must be in good health to be eligible.
  • All candidates must receive routine medical (history and physical) exam with standard laboratory tests (complete blood chemistry, urinalysis, urine pregnancy test for females, tuberculin screening), and 12-lead ECG at the initial screening visit.

Exclusion Criteria:

  • Serious psychiatric illness (e.g. psychosis, bipolar, suicide attempts, major depression that is not substance-induced).
  • Substance use disorder other than cocaine abuse or dependence, nicotine dependence, alcohol abuse, sedative abuse or marijuana abuse.
  • Neurological diseases (e.g. stroke, seizures); cardiovascular problems (e.g. myocardial infarction, angina, systolic BP >160 or <95 mmHg, diastolic BP >95 mmHg, or clinically abnormal ECG); pulmonary diseases (e.g. asthma, TB); systemic diseases (e.g. hepatitis, autoimmune diseases).
  • Cognitive impairment.
  • Exposed in past 30 days to medications that would increase study risk (e.g. toxicity to major organ systems, psychotropics, asthma inhalers, or interactions with study drugs).
  • Pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control measures (oral or depot contraceptives, IUD, condom/foam, sterilization, tubal ligation).
  • Seeking treatment or being treated for a substance use disorder.
  • Metal objects in body (e.g. metal plates, part of a bullet from a gunshot wound, or a catheter).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01392092

Locations
United States, Michigan
Wayne State University Recruiting
Detroit, Michigan, United States, 48201
Contact: Lisa Sulkowski, B.S    313-993-3966    lsulkows@med.wayne.edu   
Principal Investigator: Mark Greenwald, PhD         
Sponsors and Collaborators
Wayne State University
Investigators
Principal Investigator: Mark Greenwald, PhD Wayne State University
  More Information

No publications provided

Responsible Party: Mark Greenwald, PhD, Principal Investigator, Wayne State University
ClinicalTrials.gov Identifier: NCT01392092     History of Changes
Other Study ID Numbers: NAC-1
Study First Received: July 11, 2011
Last Updated: March 20, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Wayne State University:
Contingency Management
Drug Self-Administration

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Acetylcysteine
N-monoacetylcystine
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes

ClinicalTrials.gov processed this record on July 23, 2014